Compare BioNano Genomics Inc (BNGO) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs KKR & Co Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while KKR & Co Inc trades at $101.05 (market cap $87.28B). The key difference: KKR & Co Inc is far larger — about 6612.1× BioNano Genomics Inc's market cap, and KKR & Co Inc pays a 0.77% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | KKR | |
|---|---|---|
Market Cap | $13.20M | $87.28B |
Sector | Health | Financials |
52-Week High | $4.92 | $152.16 |
52-Week Low | $1.09 | $83.88 |
Enterprise Value | $15.81M | $12.80B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
KKR trades at $96.91, showing minimal daily movement (-0.03%). The stock maintains a bullish technical outlook with strong analyst support (89% buy ratings) and a consensus price target of $122.71, representing 27% upside potential. Recent developments include multiple strategic investments, including a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF Power Solutions' North American operations, signaling aggressive expansion.
KKR demonstrates solid fundamentals with $19.2B revenue and $2.37B net income for 2025. The company shows consistent earnings beats and strong cash flow generation. Key risks include volatile cash flow patterns and high leverage. With robust institutional backing and strategic growth initiatives, KKR appears well-positioned for continued expansion in alternative asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
